|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2001
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:available_on
|
gptkb:tablet
gptkb:capsule
Injection
|
|
gptkbp:bioavailability
|
64%
|
|
gptkbp:brand
|
gptkb:Nexium
|
|
gptkbp:casnumber
|
161796-78-7
|
|
gptkbp:category
|
Category C
|
|
gptkbp:chemical_formula
|
C17 H19 N3 O3 S
|
|
gptkbp:class
|
Proton pump inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
Severe liver impairment
Hypersensitivity to esomeprazole
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:duration
|
24 hours
|
|
gptkbp:formulation
|
Delayed-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Esomeprazole
|
|
gptkbp:interacts_with
|
gptkb:Clopidogrel
gptkb:Methotrexate
gptkb:Digoxin
gptkb:Warfarin
|
|
gptkbp:lifespan
|
1 to 1.5 hours
|
|
gptkbp:mechanism_of_action
|
Proton pump inhibition
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:nutritional_value
|
97%
|
|
gptkbp:premiered_on
|
1 hour
|
|
gptkbp:route_of_administration
|
Intravenous
Oral
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Dizziness
Fatigue
Kidney disease
Headache
Constipation
Abdominal pain
Dry mouth
Bone fractures
Liver damage
Skin reactions
Gastrointestinal infections
Low magnesium levels
|
|
gptkbp:storage
|
Room temperature
|
|
gptkbp:trade
|
gptkb:Esomeprazole_magnesium
gptkb:Nexium_IV
|
|
gptkbp:used_for
|
gptkb:Zollinger-Ellison_syndrome
Peptic ulcer disease
Gastroesophageal reflux disease (GERD)
|
|
gptkbp:bfsParent
|
gptkb:Lansoprazole
|
|
gptkbp:bfsLayer
|
6
|